Plyo

Plyo Therapeutics is a pre-clinical stage biotechnology company focused on developing a new class of medicines for obesity and metabolic diseases. The company's research is centered on the Lac-Phe (N-lactoyl-phenylalanine) pathway, an exercise-inducible metabolite that naturally suppresses appetite and improves glucose homeostasis. By developing small molecule modulators of this pathway, Plyo aims to capture the health benefits of physical activity in a pharmacological format. The company was founded by pioneers in metabolic signaling from Stanford University and Harvard Medical School and is backed by prominent life science venture capital firms.